Table 5.
Discordant response in SUVmax and TLuG in four patients
| SUVmax | TLuG | ΔLung function | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Pre | Post | Δ (%) | Pre | Post | Δ (%) | ΔFVC (%) | ΔFEV1 (%) | ΔDLCoc (%) | |
| Pt A | 11.2 | 14.7 | + 32.4 | 6606 | 5826 | − 11.8 | − 0.7 | − 5.1 | + 9.8 |
| Pt C | 2.1 | 1.6 | − 23.4 | 1827 | 2178 | + 19.2 | − 4.1 | − 5.3 | 0.0 |
| Pt D | 6.2 | 6.8 | + 9.7 | 4616 | 3596 | − 22.1 | − 10.7 | − 8.1 | − 4.8 |
| Pt E | 0.6 | 0.9 | + 50 | 2999 | 2555 | − 16.8 | − 16.7 | − 2.2 | + 4.1 |
Δ change before and after infliximab therapy, FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, DLCOc diffusing capacity of the lung for carbon monoxide corrected for haemoglobin, SUVmax maximum standardized uptake value, TLuG total lung glycolysis